According to Evotec’s quarterly figures, there are two buy recommendations for the biotech share. The analysts at Deutsche Bank have left the Evotec share on „buy”. The price target is 30 euros, but not too far above the last XETRA price of the title, which was quoted at 26.88 euros. In the study, the stock experts speak of mixed quarterly figures for the Hamburg biotech company.
Although Warburg Research confirms the buy recommendation for the Evotec share (WKN: 566480, ISIN: DE0005664809, chart ), it lowers the target price from EUR 38 to EUR 34. The reason for this is the rise in interest rates, which the experts have included in their valuation model for the biotech share. The equity experts see good growth opportunities for Evotec in the J.POD division.